Roth Capital Downgrades CorMedix (CRMD) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- US stock futures mixed as Apple slides, midterms loom
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CRMD Hot Sheet
Price: $5.39 --0%
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 15 | New: 12
Rating Summary:
11 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 15 | New: 12
Join SI Premium – FREE
Roth Capital downgraded CorMedix (NYSE: CRMD) from Buy to Neutral with a price target of $7.50 (from $2.50).
For an analyst ratings summary and ratings history on CorMedix click here. For more ratings news on CorMedix click here.
Shares of CorMedix closed at $7.60 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jersey Mike's Subs (JMKE) PT Lowered to $28 at Guggenheim
- Anhui Yingliu Electromechanical (603308:CH) PT Lowered to RMB52 at CLSA
- Sime Darby Berhad (SIME:KL) (SMEBF) PT Raised to MYR3.40 at CLSA
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Roth CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
